Annual Report · 10-K
Supernus Pharmaceuticals, Inc.
SUPNNASDAQEQUITYCurrent
Annual Report
Company context
Supernus is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Supernus’ diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
Current securities
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗